~~<i id='C5BC1D3946'><strike id='C5BC1D3946'><tt id='C5BC1D3946'><pre id='C5BC1D3946'></pre></tt></strike></i>~~

Home» explore» leisure time

leisure time

author：hotspot 2025-10-01 03:25:00 Page View：431

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Man pleads guilty to raping Ohio girl who ended up traveling across state lines for abortion
Next article： The cancer drug shortage isn’t new — and neither are the solutions

knowledge

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

AdobeSometimes,anappleadayreallyisjustwhatthedoctorordered.Andforthepastseveralyears,organizationsli

Biden slams SCOTUS affirmative action decision: 'Discrimination still exists in America'

8:47PresidentJoeBidenspeaksabouttheSupremeCourt'sdecisiontostrikedownrace-consciousstudentadmissions

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

1:19Ademonstratorrunsonthethirdnightofprotestssparkedbythefatalpoliceshootingofa17-year-olddriverint

GOP inquiry over gain

BernardMossCourtesyNIAIDFormorethanhalfacentury,scientistBernardMosshasbeencommandingtheattentionofp